---
title: "Amylyx makes $350M public stock offering in wake of avexitide results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296272456.md"
description: "Amylyx makes $350M public stock offering in wake of avexitide results"
datetime: "2026-08-18T21:31:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296272456.md)
  - [en](https://longbridge.com/en/news/296272456.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296272456.md)
generator: "portal-rs"
---

# Amylyx makes $350M public stock offering in wake of avexitide results


### Related Stocks

- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)

## Related News & Research

- [39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP](https://longbridge.com/en/news/296452266.md)
- [AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial](https://longbridge.com/en/news/296265581.md)
- [AMLX: Avexitide achieved a 55% reduction in severe hypoglycemic events in PBH, with strong safety data](https://longbridge.com/en/news/296234006.md)
- [Amylyx Says Phase 3 Trial of Avexitide For Post-Bariatric Hypoglycemia Met Main Goal](https://longbridge.com/en/news/296218787.md)
- [Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock | AMLX Stock News](https://longbridge.com/en/news/296428560.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**